# Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

> **NCT07490353** · PHASE1 · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 85 (estimated)

## Conditions studied

- Depression - Major Depressive Disorder
- Anhedonia

## Interventions

- **DRUG:** Psilocybin (Usona Institute)
- **DRUG:** Risperidone 1 MG
- **DIAGNOSTIC_TEST:** MRI

## Key facts

- **NCT ID:** NCT07490353
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490353, "Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07490353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*